Summitry LLC’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Summitry LLC’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,475	Closed	-$252K	–	88
2016 Q3	$252K	Hold	5,475	–	–	0.03%	78
2016 Q2	$275K	Hold	5,475	–	–	0.03%	74
2016 Q1	$293K	Sell	5,475 -3,407	-38%	-$200K	0.03%	73
2015 Q4	$478K	Buy	8,882 +1,600	+22%	+$98.9K	0.05%	56
2015 Q3	$411K	Sell	7,282 -3,965	-35%	-$257K	0.05%	54
2015 Q2	$658K	Sell	11,247 -252,702	-96%	-$15.6M	0.08%	41
2015 Q1	$16.4M	Sell	263,949 -179,532	-40%	-$10.4M	1.92%	27
2014 Q4	$25.5M	Buy	443,481 +655	+0.1%	+$36.5K	2.82%	16
2014 Q3	$23.8M	Buy	442,826 +1,553	+0.4%	+$82.3K	2.95%	13
2014 Q2	$23.1M	Buy	441,273 +5,000	+1%	+$256K	2.94%	15
2014 Q1	$23.1M	Buy	436,273 +6,315	+1%	+$292K	2.97%	11
2013 Q4	$17.2M	Buy	429,958 +24,054	+6%	+$947K	2.27%	21
2013 Q3	$15.3M	Buy	405,904 +9,573	+2%	+$373K	2.32%	22
2013 Q2	$15.5M	Buy	+396,331	New	+$15.4M	2.44%	22

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Summitry LLC's TEVA Position: Q4 2016 in Review

Summitry LLC sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2016, closing a stake of 5,475 shares — an estimated $252K sold.

Summitry LLC first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $25.5M in Q4 2014. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Summitry LLC reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2016 after selling out during the quarter.
Summitry LLC sold 5,475 Teva Pharmaceutical Industries Limited shares in Q4 2016, an estimated $252K.
Summitry LLC first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 14 quarters.
Summitry LLC's Teva Pharmaceutical Industries Limited position peaked at $25.5M in Q4 2014.
739 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2016.

Based on Summitry LLC's 13F filing for Q4 2016, filed 14 Feb 2017.